Is COUGH a side effect of SORAFENIB (RAF KINASE INHIBITOR) ? ( FactMed.com )

About this FactMed analysis covering adverse side effect reports of SORAFENIB (RAF KINASE INHIBITOR) patients who developed COUGH.

FactMed provides MD-approved analysis to help both patients, researchers, and physicians accurately assess the risk profile for more than 20,000 different pharmaceutical products. The below report offers compiled information from Food & Drug Administration and FactMed user submissions. Between January 2004 and October 2012, 25 individuals taking SORAFENIB (RAF KINASE INHIBITOR) reported COUGH to the FDA. A total of 3329 SORAFENIB (RAF KINASE INHIBITOR) drug adverse event reaction reports were made with the FDA during this time period. Often the FDA only receives reports of the most critical and severe cases; these numbers may therefore underrepresent the complication rate of the medication.

FDA Research Report

Introduction This page is designed to help you determine the relationship, if any, between SORAFENIB (RAF KINASE INHIBITOR) and COUGH. In doing so, we compare SORAFENIB (RAF KINASE INHIBITOR) with other drugs that cause COUGH, to help you evaluate whether or not SORAFENIB (RAF KINASE INHIBITOR) causes COUGH. Likewise, this page shows the most highly-reported side effects of SORAFENIB (RAF KINASE INHIBITOR), so you can see if COUGH ranks among SORAFENIB (RAF KINASE INHIBITOR)'s most well-known side effects.

Summary Statistics
Reports of SORAFENIB (RAF KINASE INHIBITOR) causing COUGH: 25
Reports of any side effect of SORAFENIB (RAF KINASE INHIBITOR) : 3329
Percentage of SORAFENIB (RAF KINASE INHIBITOR) patients where COUGH is a reported side effect: 0.7510%

FDA reports of any drug causing COUGH : 52647
Average percentage for all medicated patients where COUGH is reported as a complication: 0.3300%

Physician opinion on SORAFENIB (RAF KINASE INHIBITOR) as adverse event culprit:

Overall opinion for all reports of this drug:

Most frequent diagnoses/indications for prescribing SORAFENIB (RAF KINASE INHIBITOR):

HEPATIC NEOPLASM MALIGNANT ( 770 patients )
RENAL CELL CARCINOMA ( 114 patients )
THYROID CANCER ( 65 patients )
METASTATIC RENAL CELL CARCINOMA ( 44 patients )
THYROID CANCER METASTATIC ( 35 patients )
BREAST CANCER ( 31 patients )
BREAST CANCER METASTATIC ( 27 patients )
GASTRIC CANCER ( 25 patients )
NON-SMALL CELL LUNG CANCER ( 25 patients )
COLORECTAL CANCER METASTATIC ( 22 patients )
RENAL CANCER ( 17 patients )
PRODUCT USED FOR UNKNOWN INDICATION ( 14 patients )
BILE DUCT CANCER ( 14 patients )
SALIVARY GLAND CANCER ( 7 patients )
HEPATIC CANCER METASTATIC ( 7 patients )
COLORECTAL CANCER ( 7 patients )
SMALL CELL LUNG CANCER STAGE UNSPECIFIED ( 6 patients )
RECTAL CANCER ( 5 patients )
PANCREATIC CARCINOMA ( 4 patients )
PROSTATE CANCER ( 4 patients )
INTRAOCULAR MELANOMA ( 4 patients )
HEPATIC NEOPLASM MALIGNANT RECURRENT ( 3 patients )
NEOPLASM ( 3 patients )
LIVER DISORDER ( 3 patients )
ANGIOSARCOMA ( 3 patients )
NON-SMALL CELL LUNG CANCER STAGE IV ( 3 patients )
METASTASES TO LUNG ( 3 patients )
HEPATIC NEOPLASM MALIGNANT NON-RESECTABLE ( 3 patients )
COLORECTAL CANCER STAGE IV ( 3 patients )
NEOPLASM MALIGNANT ( 3 patients )
GALLBLADDER CANCER METASTATIC ( 3 patients )
BILIARY CANCER METASTATIC ( 3 patients )
METASTASIS ( 3 patients )
COLON CANCER METASTATIC ( 2 patients )
HYPOPHARYNGEAL CANCER ( 2 patients )
DESMOID TUMOUR ( 2 patients )
NEUROENDOCRINE CARCINOMA ( 2 patients )
ACUTE MYELOID LEUKAEMIA (IN REMISSION) ( 2 patients )
LUNG NEOPLASM MALIGNANT ( 2 patients )
OESOPHAGEAL CARCINOMA ( 2 patients )
METASTATIC MALIGNANT MELANOMA ( 2 patients )
TONGUE NEOPLASM MALIGNANT STAGE UNSPECIFIED ( 2 patients )
METASTATIC SQUAMOUS CELL CARCINOMA ( 2 patients )
ANGINA PECTORIS ( 2 patients )
RENAL CELL CARCINOMA STAGE IV ( 2 patients )
OSTEOSARCOMA METASTATIC ( 2 patients )
BONE SARCOMA ( 2 patients )
METASTATIC OCULAR MELANOMA ( 2 patients )
METASTATIC SALIVARY GLAND CANCER ( 2 patients )
TONSIL CANCER ( 2 patients )
MYELODYSPLASTIC SYNDROME ( 1 patients )
PROSTATE CANCER METASTATIC ( 1 patients )
GALLBLADDER CANCER ( 1 patients )
NEUROENDOCRINE TUMOUR ( 1 patients )
MALIGNANT NEOPLASM OF RENAL PELVIS ( 1 patients )
GLIOMA ( 1 patients )
BLADDER CANCER ( 1 patients )
OVARIAN CANCER METASTATIC ( 1 patients )
CAROTID ARTERY DISEASE ( 1 patients )
HEPATOBLASTOMA ( 1 patients )
NASOPHARYNGEAL CANCER ( 1 patients )
ACUTE MYELOID LEUKAEMIA ( 1 patients )
LUNG ADENOCARCINOMA ( 1 patients )
RENAL CANCER METASTATIC ( 1 patients )
DIFFUSE LARGE B-CELL LYMPHOMA ( 1 patients )
NEUROENDOCRINE CARCINOMA OF THE SKIN ( 1 patients )
MALIGNANT HISTIOCYTOSIS ( 1 patients )
ANTICOAGULANT THERAPY ( 1 patients )
MALIGNANT SOFT TISSUE NEOPLASM ( 1 patients )
SARCOMA ( 1 patients )
GERM CELL CANCER ( 1 patients )
OESOPHAGEAL ADENOCARCINOMA ( 1 patients )
SQUAMOUS CELL CARCINOMA ( 1 patients )
HEAD AND NECK CANCER ( 1 patients )
OVARIAN EPITHELIAL CANCER ( 1 patients )
( 0 patients )

Drugs with high FDA adverse event association with COUGH:

HUMIRA (4802 patients)
ASPIRIN (4583 patients)
FOSAMAX (4558 patients)
ENBREL (3869 patients)
VIOXX (3012 patients)
PREDNISONE (2705 patients)
METHOTREXATE (2523 patients)
LISINOPRIL (2479 patients)
ADVAIR DISKUS 100/50 (2377 patients)
NEXIUM (2277 patients)
LIPITOR (2205 patients)
SPIRIVA (2160 patients)
ALBUTEROL (2112 patients)
ZOMETA (1900 patients)
LASIX (1756 patients)
SYNTHROID (1703 patients)
REMICADE (1699 patients)
XOLAIR (1678 patients)
FOLIC ACID (1668 patients)
OMEPRAZOLE (1599 patients)
COUMADIN (1493 patients)
SINGULAIR (1463 patients)
HYDROCHLOROTHIAZIDE (1432 patients)
SIMVASTATIN (1387 patients)
FUROSEMIDE (1384 patients)
FORTEO (1374 patients)
PRILOSEC (1369 patients)
ATENOLOL (1276 patients)
NORVASC (1217 patients)
DIGOXIN (1196 patients)
LEVOTHYROXINE SODIUM (1177 patients)
AREDIA (1169 patients)
SYMBICORT (1166 patients)
PLAVIX (1145 patients)
TOPROL-XL (1138 patients)
XANAX (1134 patients)
ZOCOR (1132 patients)
NEURONTIN (1115 patients)
DIOVAN (1105 patients)
ACETAMINOPHEN (1095 patients)
VITAMIN D (1084 patients)
SEROQUEL (1080 patients)
PREDNISONE TAB (1067 patients)
PROTONIX (1064 patients)
CELEBREX (1061 patients)
PREVACID (1035 patients)
ZOLOFT (1017 patients)
IBUPROFEN (988 patients)
POTASSIUM CHLORIDE (965 patients)
TYSABRI (959 patients)
PREDNISOLONE (958 patients)
AMBIEN (943 patients)
CALCIUM (923 patients)
VICODIN (921 patients)
ATIVAN (906 patients)
CRESTOR (889 patients)
HEPARIN SODIUM INJECTION (884 patients)
DEXAMETHASONE (863 patients)
METFORMIN HCL (859 patients)
LEVAQUIN (858 patients)
SYNAGIS (845 patients)
SANDOSTATIN LAR (829 patients)
PAXIL (810 patients)
ALLOPURINOL (786 patients)
VENTOLIN (774 patients)
OXYCONTIN (764 patients)
PREMARIN (762 patients)
CHANTIX (758 patients)
LANTUS (750 patients)
ZYRTEC (749 patients)
MULTI-VITAMINS (748 patients)
LEXAPRO (738 patients)
WARFARIN SODIUM (737 patients)
GLEEVEC (718 patients)
AMLODIPINE (716 patients)
AVONEX (711 patients)
PEGASYS (687 patients)
COMBIVENT (677 patients)
SOLIRIS (676 patients)
LYRICA (670 patients)
COREG (669 patients)
BENADRYL (665 patients)
CYMBALTA (659 patients)
METOPROLOL TARTRATE (657 patients)
PERCOCET (655 patients)
GABAPENTIN (650 patients)
ALLEGRA (639 patients)
FLOVENT (639 patients)
AMOXICILLIN (637 patients)
ZITHROMAX (634 patients)
BYETTA (625 patients)
LORAZEPAM (614 patients)
MULTI-VITAMIN (614 patients)
ALTACE (614 patients)
DECADRON (608 patients)
COZAAR (599 patients)
FLONASE (597 patients)
ZOFRAN (592 patients)
ZANTAC (589 patients)
EFFEXOR (588 patients)
AFINITOR (582 patients)
FISH OIL (574 patients)
CYCLOPHOSPHAMIDE (574 patients)
REVLIMID (562 patients)
INSULIN (561 patients)
CELEXA (559 patients)
TYLENOL (CAPLET) (557 patients)
ASCORBIC ACID (555 patients)
CALCIUM CARBONATE (553 patients)
NITROGLYCERIN (551 patients)
PROZAC (549 patients)
SPIRONOLACTONE (549 patients)
VITAMIN E (544 patients)
WELLBUTRIN (533 patients)
EXJADE (530 patients)
FOSAMAX PLUS D (529 patients)
DIAZEPAM (527 patients)
GLUCOPHAGE (522 patients)
ALPRAZOLAM (522 patients)
ACTONEL (521 patients)
BACTRIM (515 patients)
FLEXERIL (512 patients)
RANITIDINE (511 patients)
ALENDRONATE SODIUM (506 patients)
ACCUTANE (499 patients)
CLONAZEPAM (496 patients)
RIBAVIRIN (490 patients)
LORTAB (489 patients)
OXYCODONE HCL (487 patients)
KLONOPIN (485 patients)
TRACLEER (485 patients)
TRAMADOL HCL (482 patients)
METOPROLOL (478 patients)
CLARITIN (446 patients)
NASONEX (445 patients)
ARIMIDEX (444 patients)
AZITHROMYCIN (443 patients)
CIPROFLOXACIN (435 patients)
TAXOTERE (434 patients)
ENALAPRIL MALEATE (432 patients)
MORPHINE (431 patients)
NIASPAN (421 patients)
VITAMIN B-12 (421 patients)
AVELOX (418 patients)
RAMIPRIL (416 patients)
GLIPIZIDE (414 patients)
FLOMAX (414 patients)
ACYCLOVIR (411 patients)
FEMARA (407 patients)
GILENYA (406 patients)
VALIUM (404 patients)
ALDACTONE (400 patients)
TRAZODONE HCL (400 patients)
TYLENOL (398 patients)
CLONIDINE (396 patients)
ACTOS (395 patients)
ZETIA (395 patients)
CARVEDILOL (395 patients)
REGLAN (388 patients)
CYCLOSPORINE (381 patients)
CARBOPLATIN (379 patients)
COMPAZINE (379 patients)
NEXAVAR (378 patients)
HUMALOG (375 patients)
MAGNEVIST (372 patients)
FLUCONAZOLE (371 patients)
VELCADE (369 patients)
AMITRIPTYLINE HCL (368 patients)
ATROVENT (367 patients)
ARANESP (367 patients)
COLACE (366 patients)
NAPROXEN (360 patients)
PEPCID (360 patients)
FERROUS SULFATE TAB (359 patients)
LANSOPRAZOLE (359 patients)
OXYGEN (358 patients)
POTASSIUM (357 patients)
GLYBURIDE (357 patients)
HYDROCODONE (352 patients)
METFORMIN (349 patients)
THALIDOMIDE (349 patients)
SEREVENT (349 patients)
AVANDIA (345 patients)
CHEMOTHERAPEUTICS NOS (340 patients)
ZESTRIL (340 patients)
PULMICORT (339 patients)
RISPERDAL (338 patients)
ADVAIR HFA (338 patients)
CLOZARIL (337 patients)
AUGMENTIN '125' (336 patients)
LOVENOX (333 patients)
IRON (333 patients)
LOSARTAN POTASSIUM (333 patients)
PLAQUENIL (333 patients)
ZYPREXA (333 patients)
VERAPAMIL (330 patients)
CLARITHROMYCIN (329 patients)
LOPRESSOR (328 patients)
CLINDAMYCIN (325 patients)
VENTAVIS (320 patients)
BENICAR (313 patients)
FLUOROURACIL (312 patients)
DOXYCYCLINE (312 patients)
CARDIZEM (312 patients)
TEMAZEPAM (310 patients)
FORASEQ (310 patients)
XELODA (309 patients)
VANCOMYCIN (309 patients)
HERCEPTIN (308 patients)
BONIVA (308 patients)

Most common side effects for patients taking SORAFENIB (RAF KINASE INHIBITOR):

DIARRHOEA (613 patients)
HEPATIC FAILURE (378 patients)
PALMAR-PLANTAR ERYTHRODYSAESTHESIA SYNDROME (342 patients)
HEPATIC ENCEPHALOPATHY (320 patients)
FATIGUE (300 patients)
RASH (276 patients)
ASCITES (253 patients)
ABDOMINAL PAIN (237 patients)
DECREASED APPETITE (226 patients)
UPPER GASTROINTESTINAL HAEMORRHAGE (198 patients)
PYREXIA (191 patients)
ASPARTATE AMINOTRANSFERASE INCREASED (179 patients)
NAUSEA (165 patients)
HYPERTENSION (160 patients)
ASTHENIA (154 patients)
DEHYDRATION (140 patients)
HEPATIC FUNCTION ABNORMAL (133 patients)
DYSPNOEA (131 patients)
CONFUSIONAL STATE (131 patients)
HYPOKALAEMIA (125 patients)
ALOPECIA (124 patients)
VOMITING (118 patients)
CONSTIPATION (115 patients)
INTERSTITIAL LUNG DISEASE (114 patients)
LEFT VENTRICULAR DYSFUNCTION (113 patients)
DEATH (113 patients)
ENDOCARDITIS (112 patients)
ARTHRALGIA (111 patients)
STOMATITIS (111 patients)
ABDOMINAL PAIN UPPER (110 patients)
JAUNDICE (108 patients)
HEPATIC NEOPLASM MALIGNANT (106 patients)
GASTROINTESTINAL HAEMORRHAGE (106 patients)
RETINAL VASCULAR THROMBOSIS (103 patients)
LOWER GASTROINTESTINAL HAEMORRHAGE (103 patients)
LIVER CARCINOMA RUPTURED (101 patients)
OEDEMA PERIPHERAL (97 patients)
PLEURAL EFFUSION (97 patients)
STAPHYLOCOCCAL INFECTION (96 patients)
PNEUMONIA BACTERIAL (96 patients)
ENTEROBACTER INFECTION (96 patients)
MYOPATHY (95 patients)
DRY MOUTH (94 patients)
PAIN IN EXTREMITY (93 patients)
ANXIETY (90 patients)
MALAISE (89 patients)
PULMONARY EMBOLISM (85 patients)
ANAEMIA (84 patients)
PLATELET COUNT DECREASED (81 patients)
BACK PAIN (79 patients)
SEPSIS (78 patients)
PRURITUS (78 patients)
DUODENAL ULCER (77 patients)
MIGRAINE (76 patients)
MITRAL VALVE INCOMPETENCE (76 patients)
HYPOGLYCAEMIA (76 patients)
C-REACTIVE PROTEIN INCREASED (74 patients)
BLOOD PRESSURE INCREASED (73 patients)
VARICES OESOPHAGEAL (73 patients)
HEADACHE (72 patients)
RETINAL VEIN OCCLUSION (72 patients)
ABASIA (69 patients)
RENAL FAILURE ACUTE (69 patients)
WEIGHT DECREASED (67 patients)
DEEP VEIN THROMBOSIS (67 patients)
DIZZINESS (65 patients)
ERYTHEMA (65 patients)
GENERAL PHYSICAL HEALTH DETERIORATION (64 patients)
CONVULSION (63 patients)
ALANINE AMINOTRANSFERASE INCREASED (62 patients)
DYSPHONIA (62 patients)
CEREBRAL HAEMORRHAGE (60 patients)
APHAGIA (58 patients)
COLITIS (58 patients)
PNEUMONIA (57 patients)
GASTRIC ULCER (56 patients)
HYPONATRAEMIA (55 patients)
HAEMOGLOBIN DECREASED (53 patients)
RESPIRATORY FAILURE (52 patients)
LUNG DISORDER (52 patients)
CEREBRAL ISCHAEMIA (49 patients)
PARAESTHESIA (49 patients)
BLOOD BILIRUBIN INCREASED (48 patients)
GAIT DISTURBANCE (48 patients)
THYROID CANCER METASTATIC (44 patients)
DEPRESSED LEVEL OF CONSCIOUSNESS (43 patients)
PERICARDIAL EFFUSION (41 patients)
THROMBOCYTOPENIA (41 patients)
BLISTER (41 patients)
FEBRILE NEUTROPENIA (40 patients)
BLOOD LACTATE DEHYDROGENASE INCREASED (40 patients)
HALLUCINATION (40 patients)
CHILLS (40 patients)
AMMONIA INCREASED (39 patients)
SKIN ULCER (39 patients)
BLOOD ALKALINE PHOSPHATASE INCREASED (38 patients)
PAIN (38 patients)
HYPOALBUMINAEMIA (38 patients)
HYPOCALCAEMIA (37 patients)
FALL (37 patients)
POLLAKIURIA (37 patients)
BLOOD PRESSURE DECREASED (37 patients)
SKIN EXFOLIATION (37 patients)
INSOMNIA (36 patients)
CARDIAC ARREST (36 patients)
HYPOAESTHESIA (35 patients)
INFECTIOUS PERITONITIS (35 patients)
MYOCARDIAL INFARCTION (35 patients)
RETINAL VASCULAR DISORDER (34 patients)
RENAL FAILURE (34 patients)
LIPASE INCREASED (34 patients)
HYPERKALAEMIA (33 patients)
HYPERGLYCAEMIA (33 patients)
HAEMOPTYSIS (31 patients)
ATRIAL FIBRILLATION (30 patients)
GENERALISED OEDEMA (30 patients)
FAECAL INCONTINENCE (30 patients)
WHITE BLOOD CELL COUNT DECREASED (30 patients)
CELLULITIS (29 patients)
CHEST PAIN (29 patients)
SOMNOLENCE (29 patients)
HYPERBILIRUBINAEMIA (28 patients)
HYPOTENSION (28 patients)
MUSCLE SPASMS (28 patients)
ABDOMINAL DISTENSION (27 patients)
WHITE BLOOD CELL COUNT INCREASED (27 patients)
VISION BLURRED (27 patients)
HEPATIC PAIN (26 patients)
BLOOD ALBUMIN DECREASED (26 patients)
DYSURIA (25 patients)
RASH GENERALISED (25 patients)
BLOOD SODIUM DECREASED (25 patients)
BLOOD URIC ACID INCREASED (25 patients)
COMA (25 patients)
COUGH (25 patients)
PANCYTOPENIA (25 patients)
ACUTE ABDOMEN (24 patients)
EOSINOPHIL COUNT INCREASED (24 patients)
CEREBROVASCULAR ACCIDENT (24 patients)
METASTASES TO CENTRAL NERVOUS SYSTEM (23 patients)
CEREBRAL INFARCTION (23 patients)
HYPOMAGNESAEMIA (23 patients)
RETINAL VEIN THROMBOSIS (23 patients)
GAMMA-GLUTAMYLTRANSFERASE INCREASED (23 patients)
TUMOUR LYSIS SYNDROME (22 patients)
HYPOPHOSPHATAEMIA (22 patients)
INFECTION (22 patients)
ORAL PAIN (22 patients)
BLOOD CREATININE INCREASED (22 patients)
NEUTROPENIA (22 patients)
RENAL IMPAIRMENT (22 patients)
LETHARGY (22 patients)
SKIN TOXICITY (21 patients)
TONGUE BLISTERING (21 patients)
LIVER ABSCESS (21 patients)
HAEMATEMESIS (21 patients)
OESOPHAGEAL VARICES HAEMORRHAGE (20 patients)
MENTAL IMPAIRMENT (20 patients)
NERVOUSNESS (20 patients)
NEPHROTIC SYNDROME (20 patients)
HYPOPHAGIA (20 patients)
ADRENAL INSUFFICIENCY (19 patients)
DRY SKIN (19 patients)
BLOOD AMYLASE INCREASED (19 patients)
OEDEMA (19 patients)
INFECTIOUS PLEURAL EFFUSION (19 patients)
DYSPEPSIA (19 patients)
COMA HEPATIC (19 patients)
HEART RATE INCREASED (18 patients)
HYPERTENSIVE CRISIS (18 patients)
MYALGIA (18 patients)
ECZEMA (18 patients)
URINARY TRACT INFECTION (18 patients)
NEUROMYOPATHY (18 patients)
MEDICAL DEVICE COMPLICATION (18 patients)
DIVERTICULITIS (18 patients)
OSTEOMYELITIS (18 patients)
CEREBRAL ATROPHY (18 patients)
CEREBRAL VENTRICLE DILATATION (18 patients)
DIABETIC FOOT INFECTION (18 patients)
NECK PAIN (18 patients)
OLIGURIA (17 patients)
GASTROINTESTINAL DISORDER (17 patients)
HAEMATOCHEZIA (17 patients)
DISSEMINATED INTRAVASCULAR COAGULATION (17 patients)
HYPOTHYROIDISM (17 patients)
TRANSAMINASES INCREASED (17 patients)
OROPHARYNGEAL PAIN (17 patients)
CHRONIC MYELOID LEUKAEMIA (17 patients)
NEOPLASM PROGRESSION (17 patients)
METASTASES TO ADRENALS (16 patients)
LYMPHOCYTE COUNT DECREASED (16 patients)
INTERNATIONAL NORMALISED RATIO INCREASED (16 patients)
MULTI-ORGAN FAILURE (16 patients)
FEAR (16 patients)
PANCREATIC CARCINOMA (16 patients)
HYPERSOMNIA (16 patients)
EPILEPSY (16 patients)
SUBARACHNOID HAEMORRHAGE (16 patients)
METASTASES TO LUNG (16 patients)
TACHYCARDIA (16 patients)
MUSCULAR WEAKNESS (16 patients)
KLEBSIELLA SEPSIS (16 patients)
MYOCARDIAL ISCHAEMIA (16 patients)
DYSGEUSIA (16 patients)
LUNG INFECTION (16 patients)
FAECES DISCOLOURED (16 patients)
PAIN OF SKIN (16 patients)
SPINAL FRACTURE (16 patients)
PANIC REACTION (16 patients)

In addition to reviewing our up-to-date FDA research, users may interact with the FactMed community - currently one million members and growing! FactMed online research and discussions are read by patients, scientists, physicians, and other interested health care parties. Post follow up Questions to learn from our diverse readership. Likewise, patients who have experienced unwanted effects are encouraged to share their Concerns to help educate and inform our members.

Recent FactMed Activity for SORAFENIB (RAF KINASE INHIBITOR)

Issue	Description / Topic	Timestamp

My Patient Resources

Get your questions answered! Over one million patients, researchers, and health care providers have visited FactMed. If you have a question about COUGH and SORAFENIB (RAF KINASE INHIBITOR), post it here. You may receive a response from a fellow patient - or a leading expert in the field.

Your Question:

Share your experience: Over one million patients, researchers, and health care providers have visited FactMed. If you have a noteworthy experience as a patient taking SORAFENIB (RAF KINASE INHIBITOR), post it here. Your story could help a fellow patient - or provide insight to a leading expert in the field.

Your Experience or Concern:

Telemedicine Expert Consults FactMed newest feature allows patients to consult - via realtime videoconferencing - experts in SORAFENIB (RAF KINASE INHIBITOR). This premium feature connects patients to experts, regardless of geography. FactMed experts charge reasonable rates that may be reimbursable by your insurance as a second-opinion.

We are currently accepting registration for SORAFENIB (RAF KINASE INHIBITOR) experts. If you are a healthcare provider experienced in prescribing SORAFENIB (RAF KINASE INHIBITOR), please register here.